(Q31401575)

2 July 2017

1 reference

title

The use of leflunomide in the treatment of rheumatoid arthritis: an experimental and clinical review (English)

1 reference

2 July 2017

1 reference

Schattenkirchner M

1

1 reference

2 July 2017

language of work or name

1 reference

1 May 2000

1 reference

2 July 2017

1 reference

2 July 2017

volume

47

1 reference

2 July 2017

issue

2-3

1 reference

2 July 2017

page(s)

291-298

1 reference

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

2 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900194-6

7 January 2021

Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity--I. Disease modifying action on adjuvant arthritis of the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900194-6

7 January 2021

Leflunomide interferes with pyrimidine nucleotide biosynthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900194-6

7 January 2021

T-lymphocytes from AIDS patients are unable to synthesize ribonucleotides de novo in response to mitogenic stimulation. Impaired pyrimidine responses are already evident at early stages of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900194-6

7 January 2021

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900194-6

7 January 2021

Immunomodulation of proteoglycan-induced progressive polyarthritis by lefluflomide

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900194-6

7 January 2021

Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900194-6

7 January 2021

Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900194-6

7 January 2021

Disease modifying activity of HWA 486 in rat adjuvant-induced arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900194-6

7 January 2021

Preliminary criteria for clinical remission in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900194-6

7 January 2021

Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900194-6

7 January 2021

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900194-6

7 January 2021

Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900194-6

7 January 2021

Immunomodulation of rat antigen-induced arthritis by leflunomide alone and in combination with cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900194-6

7 January 2021

Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900194-6

7 January 2021

10.1016/S0162-3109(00)00194-6

Identifiers

DOI

1 reference

2 July 2017

1 reference